1,328 research outputs found
Novel active pharmaceutical ingredients from India: The issues—part-II
No full textIndia has made a mark by discovering at least 16 novel synthetic active pharmaceutical ingredients (APIs). However, this number is quite small when compared with the number of APIs invented the world over in the allopathic system of medicines, the numbers of which according to the estimate of the author stand at more than 5000, of which presently nearly 3000 numbers are in therapeutic use against human diseases/ailments. In India, nearly 2200 numbers of these APIs are presently in use. India has made a mark in the supply of branded generic and generic formulations for use in the country and abroad in an environment of cut-throat competition. To maintain and improve the mark, India needs to carry out R&D not only for process innovation but would also have to invest and invent novel APIs. The analysis shows that the present investment in R&D and the policies followed for promoting research for new drug development are not adequate for the country to be dominant global player. Suggestions have been made to improve the present situation
Ghosh, the shadow lines, and the Indian-English novel
No full textThe prizewinning author of novels, nonfiction, and hybrid texts, Amitav Ghosh grew up in India and trained as an anthropologist. His works have been translated in over thirty languages. They cross and mix a number of genres, from science fiction to the historical novel, incorporating ethnohistory and travelogue and even recuperating dead languages. His subjects include climate change, postcolonial identities, translocation, migration, oceanic spaces, and the human interface with the environment
Human vaccines industry in China, 2019: Part—I
No full textChina is presently the most populous country; the annual birth rate is estimated at above 18 million each year over the next 5 years. The number of the aged population is also increasing. Continuous in-country demand for vaccines will, therefore, be maintained, providing opportunities for the manufacturers. China produces a large number of vaccines, presently estimated at 55 different types, which are used to protect against 28 types of individual infectious microbial diseases. The country has presently a total of 41 vaccine manufacturing companies, of which 21 are the major ones. The manufacturing capacity appears to be over 1000 a million doses per annum and the annual production in 2019 was over 700 million doses. Chinese imports of vaccines have remained low. The major government establishment, the China National Biotec Group (CNBG) companies are the leading manufacturer of vaccines in China and supply more than 50% of all the vaccines consumed in the country. CNBG is a research-driven biotech establishment and is engaged in R&D, manufacturing, marketing, and distribution of vaccines and blood products. CNBG has six institutes of biological products besides other assets; the six institutes are also engaged in the manufacture, distribution, and sale of vaccines through their manufacturing companies and establishments in China. CNBG has seven vaccine manufacturing units. CNBG is a subsidiary of China National Pharmaceutical Group Corporation (Sinopharm). Sinopharm infrastructure shoulders the social responsibility of Chinese national medical and pharmaceutical reserve on a sustainable long-term basis, including handling of emergency situations. Sinopharm is under the State-owned Assets Supervision and Administration Commission (SASAC) of the State Council of China and is engaged in 10 core business activities that cover biopharmaceutical products, including vaccines
Utility of convalescent plasma for COVID-19 treatment
No full textThe novel coronavirus identified and designated as SARS-CoV-2 has brought unprecedented suffering to people across the globe. There is yet neither an effective therapeutic substance nor a vaccine to treat the disease. Intensive research is being carried out globally to combat the menace. The road to success is miles away as effective drugs and vaccines (when available) are to be produced in adequate quantities and supplied at affordable prices to contain the disease. The observation that deployment of already-known technique of using convalescent plasma in the treatment of microbial diseases has yielded encouraging results in treating several deadly diseases, encourage the use of convalescent plasma collected from consented donors recently recovered from COVID-19 by plasmapheresis and using those for treating critically ill patients. The upgraded facilities for such purposes need to be in place along with the regulatory requirements for ensuring donor safety and judicious entitlement of convalescent plasma in patient care
Human vaccines industry in china, 2019: Part II
No full textThere are a large number of private manufacturers of vaccines in China. Most of the Chinese private companies manufacturing vaccines were established in the decade of 1990 and thereafter. Local investors came forward to set up manufacturing facilities in an environment of China’s growing demand for human vaccines and for exports. There are at present about 34 companies operating in the private sector, including MNCs. In this review, profiles of 25 private Chinese companies have been brought out. The turnover of vaccines manufactured in China is estimated at between US3.95 billion in 2019. Although the turnover of the vaccine industry was about 2.7%–3.1%, when compared to its pharmaceutical industry in value terms, it is a very important segment of healthcare infrastructure of the country
Tuberculosis-prone countries and resistance to COVID-19
No full textThe severe acute respiratory syndrome coronavirus 2 (SARS CoV2) also called human coronavirus 2019 (HCoV-19) causing COVID-19 flu originated from China. The complete nucleotide sequence of SARS CoV2 was revealed in January 2020 by Chinese scientists, opening up opportunities for developing therapeutic agents and vaccines. The Chinese people were late in declaring the onset of the disease; only during January 2020, it was revealed that this disease was spreading like an epidemic from man to man contact. The spread of the disease and deaths, in the meantime, were very high in a short period all over the world from man to man contact. To prevent these, use of masks, social distancing among the noninfected and maintaining isolation in houses for a period to allow the surroundings to get absolved from infection, and locking down the infected in hospitals or at home with supportive therapy were effective to prevent the spread. Current country-wise world data on diseased individuals and the deaths reveal that the developing countries having a preponderance of tuberculosis perform better in comparison, to resist the disease with concomitant lesser deaths. The efforts of developing an effective vaccine would require a painstaking, precise understanding of the manner the virus mutates and mount vaccination strategies to effectively neutralize and opsonize
ENTIRE FUNCTIONS SHARING POLYNOMIALS WITH THEIR DERIVATIVES
No full textIn this paper we study the uniqueness of entire functions sharing two polynomials with their derivatives. The results of the paper improve the corresponding results of Chang and Fang (Kodai Math.J. 25(2002), 309–320) and Lahiri-Ghosh(Present author) (Analysis ,Munich. 31(2011), 47–59)
First person – Arijita Ghosh
No full textABSTRACT
First Person is a series of interviews with the first authors of a selection of papers published in Journal of Cell Science, helping early-career researchers promote themselves alongside their papers. Arijita Ghosh is the first author on “Leucine-rich repeat-containing 8B protein is associated with the endoplasmic reticulum Ca2+ leak in HEK293 cells”, published in Journal of Cell Science. Arijita is a PhD student in the laboratory of Amal Kanti Bera at the Indian Institute of Technology Madras, Chennai, India, investigating the role of leucine-rich repeat-containing 8 proteins in cellular calcium homeostasis.</jats:p
Understanding Terrorism in the context of Global Security
No full textUnderstanding Terrorism in the context of Global Security
Author / Authors : Shreyasi Ghosh
Page no. 89-106
Discipline : Political Science/Polity/ Democratic studies
Script/language : Roman/English
Category : Research paper
Keywords: Terrorism, Violence, Threat, Global Security, Globalization
Beyond national literatures: Empire and Amitav Ghosh
No full textScholarship on the writer Amitav Ghosh has addressed issues of nationalism, postcolonial identity, ecocriticism, testimony, subalternity, and historiography. But the idea of Ghosh as an Asian American author with a particular relationship to the United States and its national mythologies, has barely been considered. In this essay, I explore this neglected aspect of Ghosh’s œuvre by looking at the idea of America in his writing and by situating his work within what I term "the Bengali American grain". Reading his work alongside that of other Bengali American writers and arguing that it is more ambitious thematically and more anti-imperialistic, I probe Ghosh’s problematic relationship with the United States, asking how his hemispheric writing continues to extend and even alter the terrain often associated with Asian American literature
- …
